Article Text

Download PDFPDF
792 Circulating tumour DNA as prognostic factor in endometrial cancer – final results from an international multicenter study
  1. Franziska Siegenthaler1,
  2. Karin Teien Lande2,
  3. Camilla Krakstad3,4,
  4. Carlos Casas Arozamena5,2,6,
  5. Daniel Nebdal2,
  6. Erling A Høivik3,4,
  7. Sara Imboden1,
  8. Tilman T Rau7,
  9. Ben Davidson8,9,
  10. Michael D Mueller1,
  11. Rose Gold4,
  12. Therese Sørlie2,9 and
  13. Kristina Lindemann10,9
  1. 1Department of Obstetrics and Gynecology, Bern University Hospital and University of Bern, Bern, Switzerland
  2. 2Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
  3. 3Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
  4. 4Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
  5. 5Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Santiago De Compostela, Spain
  6. 6University of Santiago de Compostela, Santiago de Compostela, Spain
  7. 7Institute of Pathology, Universitätsklinikum Düsseldorf, Düsseldorf, Germany
  8. 8Department of Pathology, Norwegian Radium Hospital, Oslo Univerisity Hospital, Oslo, Norway
  9. 9Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
  10. 10Department of Gynaecological Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway


Introduction/Background Analysis of circulating tumour DNA (ctDNA) is a promising non-invasive technique that may serve as a diagnostic, prognostic, and disease-monitoring marker. Aim of this study is to investigate the association of ctDNA with clinicopathological characteristics and oncological outcome in endometrial cancer patients.

Methodology Blood plasma samples were collected pre-operatively from 83 patients diagnosed with endometrial cancer and treated at the Bern University Hospital, Switzerland (n= 36), Oslo University Hospital (n= 34) and Haukeland University Hospital (n= 13), Norway. cfDNA was isolated and selected mutations were detected using the Oncomine™ Pan-Cancer cell free assay. Comparative analysis of whole exome sequencing data from tumour tissue was performed.

Results Baseline clinicopathological data and their association with ctDNA status are provided in table 1. Mean concentration of cfDNA was 11.4 ng/ml. 16 (19.3%) patients were considered ctDNA positive with at least one mutation found in plasma. Mutations in ctDNA were found for the following genes: TP53, ESR1, CTNNB1, PIK3CA, KRAS, NRAS, GNAS, and CCND3. Most mutations were concordant between the solid and liquid biopsies. Interestingly, although 52% of patients presented mutations in PTEN in their primary tumour, the same alteration was not found in the ctDNA. Mean follow-up was 45.7 months. Patients with positive ctDNA presented with a significantly shorter recurrence-free (P= .048) and disease-specific (P= .014) survival compared to ctDNA negative patients. In multivariable Cox regression analysis including stage, histological subtype, grading, and lymphovascular space invasion, ctDNA positivity remained an independent predictor of recurrence (HR 6.0, 95% CI 1.7 – 21.4, p= .009) and disease-specific death (HR 19.4, 95% CI 2.7 – 139.7, p= .004).

Conclusion This study shows the feasibility of using a gene panel to identify ctDNA positive patients which will facilitate its use on a larger scale. ctDNA positivity was significantly associated with worse oncological outcome.

Disclosures No conflicts of interests related to this work. This study was supported by grants from Swiss National Science Foundation, Foundation for clinical-experimental cancer research, SAKK/ Dr. Paul Jannsen Fellowship, Rakel og Otto Kristian Bruun’s Legat.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.